These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11283848)

  • 1. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 2001 Apr; 33(4):841-7. PubMed ID: 11283848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC; Toyoda M; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.
    Ng IO; Poon RT; Lee JM; Fan ST; Ng M; Tso WK
    Am J Clin Pathol; 2001 Dec; 116(6):838-45. PubMed ID: 11764072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1).
    Yamane A; Seetharam L; Yamaguchi S; Gotoh N; Takahashi T; Neufeld G; Shibuya M
    Oncogene; 1994 Sep; 9(9):2683-90. PubMed ID: 8058332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
    Fine BA; Valente PT; Feinstein GI; Dey T
    Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.
    Takahashi T; Shibuya M
    Oncogene; 1997 May; 14(17):2079-89. PubMed ID: 9160888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
    Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
    Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
    Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.
    Takahashi T; Yamaguchi S; Chida K; Shibuya M
    EMBO J; 2001 Jun; 20(11):2768-78. PubMed ID: 11387210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental expression of vascular endothelial growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes.
    Bogic LV; Brace RA; Cheung CY
    Placenta; 2001 Apr; 22(4):265-75. PubMed ID: 11286562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
    Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
    J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
    Giatromanolaki A; Sivridis E; Athanassou N; Zois E; Thorpe PE; Brekken RA; Gatter KC; Harris AL; Koukourakis IM; Koukourakis MI
    J Pathol; 2001 May; 194(1):101-8. PubMed ID: 11329148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization.
    Suzuma K; Takagi H; Otani A; Suzuma I; Honda Y
    Microvasc Res; 1998 Nov; 56(3):183-91. PubMed ID: 9828156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.